MedTrace Logo

Safety and Efficacy of CC-10004 for Prurigo Nodularis

NCT00869089 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-11-02

Study results available
· View outcomes & findings →

Summary

This trial will include:

* Study period up to 7 months.
* Office visits monthly lasting approximately 1 hour.
* Blood Draws.
* Oral medication that is taken 2 times daily.
* Photographs and biopsies if agreed.

Conditions

  • Prurigo Nodularis

Interventions

DRUG

CC-10004

30mg,oral medication, BID, for 24 weeks (60mg total DAILY)

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • University Hospitals Cleveland Medical Center

    lead OTHER

Principal Investigators

  • Neil Korman, M.D.,PhD. · University Hospitals Cleveland Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00869089 on ClinicalTrials.gov